Goodell et al. [43] demonstrated by specifically designed his-tagged capture ELISA (based on lysate from genetically engineered Chinese hamster ovary cells) the presence of AAbs to IGFBP-2 in the sera of 4/80 (5%) breast carcinoma patients, 32/80 (40%) colorectal carcinoma patients and 2/200 (1%) healthy controls. Here, IGFBP2 is linked to breast carcinoma.